Angelini Ventures announces its participation in Elkedonia's €11.25 million seed round, marking a significant milestone in our commitment to supporting academic innovation. Elkedonia, a pioneering biotech company developing first-in-class neuroplastogens for treatment-resistant depression, represents the first startup from Argobio's portfolio to reach a commercial financing milestone.

This investment highlights our unique approach to early-stage innovation through Argobio Studio, an international venture studio we sponsor and invest in, which transforms cutting-edge academic research into breakthrough biotech companies. Elkedonia's novel approach targets the previously "undruggable" Elk1 protein, offering new hope for patients with depression, PTSD, and other neuropsychiatric disorders through non-addictive, non-hallucinogenic treatments.

This milestone validates our strategy of supporting exceptional European academic research from the earliest stages, ensuring breakthrough discoveries reach patients who need them most.

Read the full press release and download additional materials to learn more about this groundbreaking investment

• International version
• Italian version